erlotinib hydrochloride has been researched along with Cancer of the Tongue in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celik, B; Demirag, MK; Elmali, M; Gulel, O | 1 |
| Bauman, JE; Carter, SL; Chiosea, S; Close, D; Du, Y; Duvvuri, U; Egloff, AM; Garraway, LA; Getz, G; Gilbert, BR; Goetz, EM; Golub, TR; Grandis, JR; Johnson, JT; Johnston, PA; Li, H; Lui, VW; McKenna, A; Mills, GB; Pendleton, KP; Sougnez, C; Stransky, N; Van Allen, EM; Wagle, N; Wang, L; Zeng, Y; Zhang, F | 1 |
| Huang, K; Liu, D | 1 |
3 other study(ies) available for erlotinib hydrochloride and Cancer of the Tongue
| Article | Year |
|---|---|
A rare complication of metastatic lung disease treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Pericardium; Tomography, X-Ray Computed; Tongue Neoplasms | 2017 |
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Phenotype; Phosphorylation; Predictive Value of Tests; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tongue Neoplasms; Treatment Outcome | 2015 |
Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Hydroxychloroquine; RNA, Small Interfering; Sirolimus; Tongue Neoplasms; Up-Regulation | 2016 |